ArticleJournal of pharmaceutical policy and practice2026
Assessment of pricing, availability, and affordability of essential medicines in a resource-limited setting.
Article in Journal of pharmaceutical policy and practice, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Access to essential medicine is a worldwide issue, driven by high prices, low affordability and limited availability. Under funded health systems, weak local production, poor supply chain governance, and discriminatory policies are the main hurdles. Low and middle-income countries are continuously making efforts to improve healthcare services. To evaluate the extent to which the intended objectives have been met, the present study undertakes an investigation into the pricing, availability, and affordability of selected essential medicines in Pakistan. Methods: A survey of 50 essential medicines, including 14 from the global core list and 36 selected from the national essential medicine list, was carried out from November 2025 to February 2026, using an adaptation of WHO/HAI methodology in five geographical areas of Pakistan. Data were acquired from 9 pharmacies of government hospitals and 18 retail pharmacies of the private sector. Prices were evaluated on the basis of the Median Price Ratio (MPR); affordability was determined by estimating how many days a minimum salaried employee of the government must spend to buy the prescribed regimen. Results: In the public sector mean availability was 12.65% (IB), 36.2% (LPG) and in private sector it was 45.7% (IB) and 55.2% (LPG). In private retail pharmacies, 13.61% were stocked with oncology medicines. Median price ratios in the private sector varied between 0.11-6.85 for LPG and 0.17-23.37 for IB. Median price ratio of 12 medicines (out of 36 calculated for MPR) was approximately similar between LPG and IB. However, prices for cardiovascular and antidiabetic medicines increased. Conclusion: Availability of LPGs has improved in the private sector. Median price ratios have decreased over time, but medicines are still unaffordable, especially for diabetes, viral, fungal and bacterial infectious diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.